Challenges and solutions for a rational vaccine design for TB-endemic regions

References

• Agrewala JN, Deacock S, Jurcevic S, Wilkinson R. (1997). Peptide recognition by T-cell clones of an HLA-DRB1*1501/*0901 heterozygous donor is promiscuous only between parental alleles. Hum Immunol 55:34–8
   PubMed Web of Science ®Google Scholar
• Agrewala JN, Wilkinson RJ. (1998). Differential regulation of Th1 and Th2 cells by p91-110 and p21-40 peptides of the 16-kD alpha-crystallin antigen of Mycobacterium tuberculosis. Clin Exp Immunol 114:392–7
   PubMed Web of Science ®Google Scholar
• Agrewala JN, Wilkinson RJ. (1999). Influence of HLA-DR on the phenotype of CD4+ T lymphocytes specific for an epitope of the 16-kDa alpha-crystallin antigen of Mycobacterium tuberculosis. Eur J Immunol 29:1753–61
   PubMed Web of Science ®Google Scholar
• Alphs HH, Gambhira R, Karanam B, et al. (2008). Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A 105: 5850–5
   PubMed Web of Science ®Google Scholar
• Andersen P, Doherty TM. (2005). The success and failure of BCG—implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3:656–62
   PubMed Web of Science ®Google Scholar
• Batzloff MR, Hartas J, Zeng W, et al. (2006). Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. J Infect Dis 194:325–30
   PubMed Web of Science ®Google Scholar
• Behar SM. (2013). Antigen-specific CD8(+) T cells and protective immunity to tuberculosis. Adv Exp Med Biol 783:141–63
   PubMed Web of Science ®Google Scholar
• Behar SM, Divangahi M, Remold HG. (2010). Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? Nat Rev Microbiol 8:668–74
   PubMed Web of Science ®Google Scholar
• Black GF, Weir RE, Floyd S, et al. (2002). BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 359:1393–401
   PubMed Web of Science ®Google Scholar
• Chackerian AA, Alt JM, Perera TV, et al. (2002). Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect Immun 70:4501–9
   PubMed Web of Science ®Google Scholar
• Chackerian AA, Perera TV, Behar SM. (2001). Gamma interferon-producing CD4+ T lymphocytes in the lung correlate with resistance to infection with Mycobacterium tuberculosis. Infect Immun 69:2666–74
   PubMed Web of Science ®Google Scholar
• Chen ZW. (2013). Multifunctional immune responses of HMBPP-specific Vgamma2Vdelta2 T cells in M. tuberculosis and other infections. Cell Mol Immunol 10:58–64
   PubMed Web of Science ®Google Scholar
• Chodisetti SB, Rai PK, Gowthaman U, et al. (2012). Potential T cell epitopes of Mycobacterium tuberculosis that can instigate molecular mimicry against host: implications in autoimmune pathogenesis. BMC Immunol 13:13
   PubMedGoogle Scholar
• Chua BY, Eriksson EM, Brown LE, et al. (2008). A self-adjuvantinglipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine 26:4866–75
   PubMed Web of Science ®Google Scholar
• Chua BY, Healy A, Cameron PU, et al. (2003). Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus. Immunol Cell Biol 81:67–72
   PubMed Web of Science ®Google Scholar
• Chua BY, Zeng W, Lau YF, Jackson DC. (2007). Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups. Vaccine 25:92–101
   PubMed Web of Science ®Google Scholar
• Colditz GA, Brewer TF, Berkey CS, et al. (1994). Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698–702
   PubMed Web of Science ®Google Scholar
• Cooper AM. (2009). Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27:393–422
   PubMed Web of Science ®Google Scholar
• Deliyannis G, Kedzierska K, Lau YF, et al. (2006). Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur J Immunol 36:770–8
   PubMed Web of Science ®Google Scholar
• Dye C. (2006). Global epidemiology of tuberculosis. Lancet 367:938–40
   PubMed Web of Science ®Google Scholar
• Eriksson EM, Jackson DC. (2007). Recent advances with TLR2-targeting lipopeptide-based vaccines. Curr Protein Pept Sci 8:412–7
   PubMed Web of Science ®Google Scholar
• Fine PE. (1995). Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346:1339–45
   PubMed Web of Science ®Google Scholar
• Flynn JL, Chan J. (2001). Immunology of tuberculosis. Annu Rev Immunol 19:93–129
   PubMed Web of Science ®Google Scholar
• Gowthaman U, Agrewala JN. (2008). Insilico tools for predicting peptides binding to HLA-class II molecules: more confusion than conclusion. J Proteome Res 7:154–63
   PubMed Web of Science ®Google Scholar
• Gowthaman U, Agrewala JN. (2009). Insilico methods for predicting T-cell epitopes: Dr Jekyll or Mr Hyde? Expert Rev Proteomics 6:527–37
   PubMed Web of Science ®Google Scholar
• Gowthaman U, Rai PK, Khan N, et al. (2012). Lipidated promiscuous peptides vaccine for tuberculosis-endemic regions. Trends Mol Med 18:607–14
   PubMed Web of Science ®Google Scholar
• Gowthaman U, Singh V, Zeng W, et al. (2011). Promiscuous peptide of 16 kDa antigen linked to Pam2Cys protects against Mycobacterium tuberculosis by evoking enduring memory T-cell response. J Infect Dis 204:1328–38
   PubMed Web of Science ®Google Scholar
• Jackson DC, Lau YF, Le T, et al. (2004). A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A 101:15440–5
   PubMed Web of Science ®Google Scholar
• Jacobsen M, Detjen AK, Mueller H, et al. (2007). Clonal expansion of CD8+ effector T cells in childhood tuberculosis. J Immunol 179:1331–9
   PubMed Web of Science ®Google Scholar
• Kaplan G, Post FA, Moreira AL, et al. (2003). Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun 71:7099–108
   PubMedGoogle Scholar
• Kaufmann SH. (2001). How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 1:20–30
   PubMed Web of Science ®Google Scholar
• Kaufmann SH. (2004). New issues in tuberculosis. Ann Rheum Dis 63:50–56
   PubMed Web of Science ®Google Scholar
• Kaufmann SH. (2010). Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 33:567–77
   PubMed Web of Science ®Google Scholar
• Khader SA, Bell GK, Pearl JE, et al. (2007). IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8:369–77
   PubMed Web of Science ®Google Scholar
• Khan N, Gowthaman U, Pahari S, Agrewala JN. (2012). Manipulation of costimulatory molecules by intracellular pathogens: veni, vidi, vici!!. PLoS Pathog 8:e1002676
   Web of Science ®Google Scholar
• Korenromp EL, Bierrenbach AL, Williams BG, Dye C. (2009). The measurement and estimation of tuberculosis mortality. Int J Tuberc Lung Dis 13:283–303
   PubMed Web of Science ®Google Scholar
• Koul A, Arnoult E, Lounis N, et al. (2011). The challenge of new drug discovery for tuberculosis. Nature 469:483–90
   PubMed Web of Science ®Google Scholar
• Kursar M, Koch M, Mittrucker HW, et al. (2007). Cutting Edge: Regulatory T cells prevent efficient clearance of Mycobacterium tuberculosis. J Immunol 178:2661–5
   PubMed Web of Science ®Google Scholar
• Lau YF, Deliyannis G, Zeng W, et al. (2006). Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. Int Immunol 18:1801–13
   PubMed Web of Science ®Google Scholar
• Lefford MJ. (1975). Transfer of adoptive immunity to tuberculosis in mice. Infect Immun 11:1174–81
   PubMed Web of Science ®Google Scholar
• Lin PL, Flynn JL. (2010). Understanding latent tuberculosis: a moving target. J Immunol 185:15–22
   PubMed Web of Science ®Google Scholar
• Lonnroth K, Castro KG, Chakaya JM, et al. (2010). Tuberculosis control and elimination 2010–50: cure, care, and social development. Lancet 375:1814–29
   PubMed Web of Science ®Google Scholar
• MacMicking JD, Taylor GA, McKinney JD. (2003). Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 302:654–9
   PubMed Web of Science ®Google Scholar
• Malhotra I, Mungai P, Wamachi A, et al. (1999). Helminth- and Bacillus Calmette-Guerin-induced immunity in children sensitized in utero to filariasis and schistosomiasis. J Immunol 162:6843–8
   PubMed Web of Science ®Google Scholar
• Montamat-Sicotte DJ, Millington KA, Willcox CR, et al. (2011). A mycolic acid-specific CD1-restricted T cell population contributes to acute and memory immune responses in human tuberculosis infection. J Clin Invest 121:2493–503
   PubMed Web of Science ®Google Scholar
• Mshana RN, Hastings RC, Krahenbuhl JL. (1988). Infection with live mycobacteria inhibits in vitro detection of Ia antigen on macrophages. Immunobiology 177:40–54
   PubMed Web of Science ®Google Scholar
• Narayanan PR. (2006). Influence of sex, age & nontuberculous infection at intake on the efficacy of BCG: re-analysis of 15-year data from a double-blind randomized control trial in South India. Indian J Med Res 123:119–24
   PubMed Web of Science ®Google Scholar
• North RJ. (1973). Importance of thymus-derived lymphocytes in cell-mediated immunity to infection. Cell Immunol 7:166–76
   PubMed Web of Science ®Google Scholar
• O’Garra A, Redford PS, McNab FW, et al. (2013). The immune response in tuberculosis. Annu Rev Immunol 31:475–527
   PubMed Web of Science ®Google Scholar
• Orme IM. (2010). The Achilles heel of BCG. Tuberculosis (Edinb) 90:329–32
   PubMed Web of Science ®Google Scholar
• Orme IM, Collins FM. (1983). Protection against Mycobacterium tuberculosis infection by adoptive immunotherapy. Requirement for T cell-deficient recipients. J Exp Med 158:74–83
   PubMed Web of Science ®Google Scholar
• Ottenhoff TH, Kaufmann SH. (2012). Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 8:e1002607
   PubMed Web of Science ®Google Scholar
• Pejoski D, Zeng W, Rockman S, et al. (2010). A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. Immunol Cell Biol 88: 605–11
   PubMed Web of Science ®Google Scholar
• Purcell AW, McCluskey J, Rossjohn J. (2007). More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6:404–14
   PubMed Web of Science ®Google Scholar
• Reiley WW, Calayag MD, Wittmer ST, et al. (2008). ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes. Proc Natl Acad Sci U S A 105:10961–6
   PubMed Web of Science ®Google Scholar
• Rook GA, Dheda K, Zumla A. (2005). Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat Rev Immunol 5:661–7
   PubMed Web of Science ®Google Scholar
• Rudd BD, Brien JD, Davenport MP, Nikolich-Zugich J. (2008). Cutting edge: TLR ligands increase TCR triggering by slowing peptide-MHC class I decay rates. J Immunol 181:5199–203
   PubMed Web of Science ®Google Scholar
• Russell DG. (2007). Who puts the tubercle in tuberculosis? Nat Rev Microbiol 5:39–47
   PubMed Web of Science ®Google Scholar
• Russell DG, Barry CE 3rd, Flynn JL. (2010). Tuberculosis: what we don't know can, and does, hurt us. Science 328:852–6
   PubMed Web of Science ®Google Scholar
• Russell DG, Cardona PJ, Kim MJ, et al. (2009). Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol 10:943–8
   PubMed Web of Science ®Google Scholar
• Schaible UE, Sturgill-Koszycki S, Schlesinger PH, Russell DG. (1998). Cytokine activation leads to acidification and increases maturation of Mycobacterium avium-containing phagosomes in murine macrophages. J Immunol 160:1290–6
   PubMed Web of Science ®Google Scholar
• Scriba TJ, Kalsdorf B, Abrahams DA, et al. (2008). Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol 180:1962–70
   PubMed Web of Science ®Google Scholar
• Sette A, Fikes J. (2003). Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15:461–70
   PubMed Web of Science ®Google Scholar
• Sette A, Rappuoli R. (2010). Reverse vaccinology: developing vaccines in the era of genomics. Immunity 33:530–41
   PubMed Web of Science ®Google Scholar
• Shafiani S, Tucker-Heard G, Kariyone A, et al. (2010). Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J Exp Med 207:1409–20
   PubMed Web of Science ®Google Scholar
• Shen Y, Zhou D, Qiu L, et al. (2002). Adaptive immune response of Vgamma2Vdelta2+ T cells during mycobacterial infections. Science 295:2255–8
   PubMed Web of Science ®Google Scholar
• Soysal A, Millington KA, Bakir M, et al. (2005). Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 366:1443–51
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Kaufmann A, Grote K, et al. (2000). Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signaling pathway. J Immunol 164:554–7
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Kawai T, Muhlradt PF, et al. (2001). Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 13:933–40
   PubMed Web of Science ®Google Scholar
• Tan AC, Deliyannis G, Bharadwaj M, et al. (2013). The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus. Immunol Cell Biol 91:96–104
   PubMedGoogle Scholar
• Tan AC, La Gruta NL, Zeng W, Jackson DC. (2011). Precursor Frequency and Competition Dictate the HLA-A2-Restricted CD8+ T Cell Responses to Influenza A Infection and Vaccination in HLA-A2.1 Transgenic Mice. J Immunol 187:1895–902
   PubMed Web of Science ®Google Scholar
• Tan ACL, Mifsud EJ, Zeng W, et al. (2012). Intranasal administration of the TLR2-agonist Pam2Cys provides rapid protection against influenza in mice. Molecular Pharmaceutics 9:2710–8
   PubMed Web of Science ®Google Scholar
• Torresi J, Stock OM, Fischer AE, et al. (2007). A self-adjuvantingmultiepitopeimmunogen that induces a broadly cross-reactive antibody to hepatitis C virus. Hepatology 45:911–20
   PubMed Web of Science ®Google Scholar
• Trunz BB, Fine P, Dye C. (2006). Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367:1173–80
   PubMed Web of Science ®Google Scholar
• Ullrich HJ, Beatty WL, Russell DG. (2000). Interaction of Mycobacterium avium-containing phagosomes with the antigen presentation pathway. J Immunol 165:6073–80
   PubMed Web of Science ®Google Scholar
• Ulrichs T, Moody DB, Grant E, et al. (2003). T-cell responses to CD1-presented lipid antigens in humans with Mycobacterium tuberculosis infection. Infect Immun 71:3076–87
   PubMed Web of Science ®Google Scholar
• vanMontfoort N, Camps MG, Khan S, et al. (2009). Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc Natl Acad Sci U S A 106:6730–5
   PubMed Web of Science ®Google Scholar
• Verma I, Grover A. (2009). Antituberculous vaccine development: a perspective for the endemic world. Expert Rev Vaccines 8:1547–53
   PubMed Web of Science ®Google Scholar
• Via LE, Lin PL, Ray SM, et al. (2008). Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 76:2333–40
   PubMed Web of Science ®Google Scholar
• Weir RE, Black GF, Nazareth B, et al. (2006). The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacilli Calmette-Guerin vaccination in southern England and northern Malawi. Clin Exp Immunol 146:390–9
   PubMed Web of Science ®Google Scholar
• WHO. (2010). WHO global tuberculosis control report 2010. Summary. Cent Eur J Public Health 18:237
   PubMedGoogle Scholar
• Winau F, Weber S, Sad S, et al. (2006). Apoptotic vesicles cross prime CD8 T cells and protect against tuberculosis. Immunity 24:105–17
   PubMed Web of Science ®Google Scholar
• Wolf AJ, Desvignes L, Linas B, et al. (2008). Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med 205:105–15
   PubMed Web of Science ®Google Scholar
• Woodworth JS, Wu Y, Behar SM. (2008). Mycobacterium tuberculosis-specific CD8+ T cells require perforin to kill target cells and provide protection in vivo. J Immunol 181:8595–603
   PubMed Web of Science ®Google Scholar
• Zeng W, Azzopardi K, Hocking D, et al. (2011a). A totally synthetic lipopeptide-based self-adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic Escherichia coli. Vaccine 30:4800–6
   Web of Science ®Google Scholar
• Zeng W, Eriksson E, Chua B, et al. (2011b). Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys. Amino Acids 39:471–80
   Web of Science ®Google Scholar
• Zeng W, Eriksson EM, Lew A, Jackson DC. (2011c). Lipidation of intact proteins produces highly immunogenic vaccine candidates. Mol Immunol 48:490–6
   PubMed Web of Science ®Google Scholar
• Zeng W, Ghosh S, Lau YF, et al. (2002). Highly immunogenic and totally synthetic lipopeptides as self-adjuvantingimmunocontraceptive vaccines. J Immunol 169:4905–12
   PubMed Web of Science ®Google Scholar